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LEARNING OBJECTIVES
After completing this course, the reader will be able to:
1. Describe the current status of phase II trials with novel agents in order to distinguish the role of phase III trials in
determining the role of novel agents.
2. Describe target therapy in stage III non-small cell lung cancer and discuss the status of personalized medicine in
stage III disease.
3. State the current standard for thoracic radiation therapy and the current status of hypofractionated, adaptive
radiotherapy and proton therapy and evaluate the recent radiation therapy oncology group (RTOG) 0617 trial.
This article is available for continuing medical education credit at CME.TheOncologist.com.CME
ABSTRACT
Approximately one third of patients with non-small cell
lung cancer have unresectable stage IIIA or stage IIIB dis-
ease, and appropriate patients are candidates for chemo-
radiotherapy with curative intent. The optimal treatment
paradigm is currently undefined. Concurrent chemoradio-
therapy, compared with sequential chemotherapy and tho-
racic radiation therapy (TRT), results in superior overall
survival outcomes as a result of better locoregional control.
Recent trials have revealed efficacy for newer chemother-
apy combinations similar to that of older chemotherapy
combinations with concurrent TRT and a lower rate of
some toxicities. Ongoing phase III trials will determine the
roles of cisplatin and pemetrexed concurrent with TRT in
patients with nonsquamous histology, cetuximab, and the
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L-BLP25 vaccine. It is unlikely that bevacizumab will have
a role in stage III disease because of its toxicity. Erlotinib,
gefitinib, and crizotinib have not been evaluated in stage
III patients selected based on molecular characteristics.
The preliminary results of a phase III trial that compared
conventionally fractionated standard-dose TRT (60 Gy)
with high-dose TRT (74 Gy) revealed an inferior survival
outcome among patients assigned to the high-dose arm.
Hyperfractionation was investigated previously with
promising results, but adoption has been limited because of
logistical considerations. More recent trials have investi-
gated hypofractionated TRT in chemoradiotherapy. Ad-
vances in tumor targeting and radiation treatment
planning have made this approach more feasible and re-
duced the risk for normal tissue toxicity. Adaptive radio-
therapy uses changes in tumor volume to adjust the TRT
treatment plan during therapy, and trials using this strat-
egy are ongoing. Ongoing trials with proton therapy will
provide initial efficacy and safety data. The Oncologist 2012;
17:682–693
INTRODUCTION
Lung cancer is the leading cause of cancer-related mortality in
the U.S. and a common cause of cancer-related mortality
worldwide [1, 2]. The majority of patients with lung cancer
have the non-small cell lung cancer (NSCLC) subtype, and ap-
proximately one third of patients have unresectable stage IIIA
or stage IIIB disease [3]. Patients with a preserved perfor-
mance status, with adequate organ function, and without sig-
nificant weight loss are candidates for chemoradiotherapy with
curative intent. There is significant heterogeneity in the patient
population who meet these criteria, which contributes to the
variability in the results of clinical trials. Most clinical trials
employ a strategy of concurrent chemoradiotherapy for locore-
gional control and systemic dose chemotherapy to prevent the
development of distant metastatic disease. Numerous trials
have investigated different agents, treatment sequences, and
radiation schedules and doses. Currently, there is no standard
of care; combined with the inherent heterogeneity in the pa-
tient population, it is therefore difficult for a clinician to select
the optimal treatment strategy for an individual patient.
Multiple trials have investigated concurrent chemoradio-
therapy versus sequential chemotherapy and thoracic radiation
therapy (TRT). A recent meta-analysis of six trials (1,205
patients) compared concurrent chemoradiotherapy with se-
quential chemotherapy followed by TRT. The meta-analysis
revealed a significant overall survival (OS) benefit (hazard ra-
tio [HR], 0.84; 95% confidence interval [CI], 0.74–0.95; p 
.004) with an absolute benefit of 4.5% at 5 years (15.1% versus
10.6%) [4]. Concurrent chemoradiotherapy resulted in a sig-
nificantly lower rate of locoregional progression (HR, 0.77;
95% CI, 0.62–0.95; p  .01) with a lower rate of local regional
progression at 5 years, 28.9% versus 35.0%. However, the
rates of distant disease progression in the concurrent and se-
quential arms were similar (HR, 1.04; 95% CI, 0.86–1.25; p 
.69) with rates of distant progression of 40.6% and 39.5% at 5
years, respectively. Concurrent chemoradiotherapy compared
with sequential chemotherapy and TRT was associated with a
significantly higher rate of grade 3 or 4 esophageal toxicity,
18% versus 4% (relative risk, 4.9; 95% CI, 3.1–7.8; p  .001).
This meta-analysis confirmed that the superior OS out-
come observed with concurrent chemoradiotherapy was re-
lated to better locoregional control. However, the high rates of
locoregional and distant disease progression and the low
5-year OS rate are quite sobering. Thus, improvements in both
locoregional and distant disease control are needed to improve
OS outcomes. Several strategies are under investigation, in-
cluding the use of more recently developed chemotherapy




Phase III trials that have revealed a statistically significant lon-
ger OS with concurrent compared to sequential chemotherapy
and radiation have used older chemotherapy combinations of
mitomycin, vindesine, and cisplatin (MVP), cisplatin and vin-
blastine, or cisplatin and etoposide [5–7]. Many clinicians
have adopted more recently developed chemotherapy agents
based on the perception that these agents have lower toxicity
and/or greater efficacy.
Several recent phase III trials have compared the newer
combinations with the older combinations (Table 1). A phase
III trial recently compared docetaxel and cisplatin weekly with
MVP plus concurrent TRT (60 Gy); the primary endpoint was
the 2-year OS rate [8]. In the planned analysis, the 2-year OS
rate favored the docetaxel and cisplatin arm over the MVP arm
(78.8% versus 70.3%; p  .059); the median survival times
(MSTs) were 26.8 months (95% CI, 23.6–33.4 months) and
23.7 months (95% CI, 15.8–33.2 months), respectively. The
rate of grade 3 or 4 febrile neutropenia was higher in the MVP
arm than in the docetaxel and cisplatin arm (39% versus 22%,
respectively), and the rate of grade 3 or 4 esophagitis was
higher in the docetaxel and cisplatin arm than in the MVP arm
(14% versus 6%; p  .056).
The West Japan Oncology Group Trial 0105 compared
MVP with TRT (60 Gy) in two investigational arms: carbopla-
tin plus irinotecan concurrent with TRT followed by two cy-
cles of carboplatin plus irinotecan and carboplatin plus
paclitaxel concurrent with TRT followed by two cycles of car-
boplatin plus paclitaxel (Table 1) [9]. The primary endpoint
was the OS time between the control arm (MVP) and the in-
vestigational arms of carboplatin plus irinotecan and carbopla-
tin plus paclitaxel. No significant differences in OS times were
observed between the investigational arms and MVP, and an
analysis did not reveal noninferiority of the investigational
arms compared with MVP. The rate of grade 3 or 4 neutrope-
nia, febrile neutropenia, gastrointestinal toxicities (nausea,
vomiting, and constipation), and fatigue were significantly
higher in the MVP arm than in the carboplatin plus irinotecan
or carboplatin plus paclitaxel arms (p  .001). The rate of
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grade 3 sensory neuropathy was higher in the carboplatin plus
paclitaxel arm than in the other arms. The rates of grade 3
esophagitis were similar in all treatment arms. In summary, ef-
ficacy was not significantly better, but lower rates of some tox-
icities were observed with the newer agents included in those
trials.
Pemetrexed has demonstrated significant activity in pa-
tients with advanced stage NSCLC, and it is currently a stan-
dard first-line, maintenance, and second-line therapy for
patients with nonsquamous histology [10–12]. Several phase
II trials have been published reporting results for pemetrexed
in combination with cisplatin or carboplatin with concurrent
TRT (Table 2) [13–17]. Of note, these trials were performed
before the interaction between histology and pemetrexed effi-
cacy was established. Overall, early results have been promis-
ing, compared with historical studies, but the ultimate efficacy
of pemetrexed cannot be determined based on the phase II trial
design, and the longer OS times observed in some of these
studies could be related to better staging with 18F-fluoro-2-
deoxy-D-glucose positron emission tomography (FDG-PET)
and patient selection than in prior studies. The rates and types
of grade 3 or 4 toxicities reported are similar to the toxicities
observed with other chemotherapy combinations used concur-
rently with TRT. An ongoing phase III trial sponsored by Eli
Lilly (ClinicalTrials.gov identifier, NCT00686959) is investi-
gating cisplatin and pemetrexed compared with cisplatin and
etoposide with TRT (66 Gy) in patients with nonsquamous his-
tology and will definitively evaluate the role of pemetrexed in
the stage III setting [18].
Epidermal Growth Factor Receptor–Targeting
Agents
Two mechanisms of targeting epidermal growth factor recep-
tor (EGFR) pathway have developed: monoclonal antibodies
that target the extracellular domain of EGFR and tyrosine ki-
nase inhibitors (TKIs) that compete with ATP for binding to
the intracellular domain of EGFR [19]. These agents have been
investigated as part of concurrent chemoradiotherapy in sev-
eral trials (Table 3). A phase III trial of cetuximab (a monoclo-
nal antibody that targets EGFR) with radiation compared with
radiation alone revealed better locoregional control and a bet-















200 Mitomycin 8 mg/m2 on day 1 60 23.7 (15.9–33.2) 16.6 (8–28.0)
Vindesine 3 mg/m2 on days 1 and 8
Cisplatin 80 mg/m2 on day 1
(every 4 weeks for 2 cycles)
Docetaxel 40 mg/m2 on days 1, 8, 29, 36 60 26.8 (23.6–33.4) 23.5 (13.8–34.7)




Mitomycin 8 mg/m2 on day 1
Vindesine 3 mg/m2 on days 1 and 8
Cisplatin 80 mg/m2 on day 1
(every 4 weeks for 2 cycles)
60 20.5 17.5
Systemic therapy:
Two additional cycles of MVP
Concurrent therapy:
Carboplatin AUC  2 weekly




Carboplatin AUC  5 on day 1
Irinotecan 50 mg/m2 on days 1 and 8
(every 3 weeks for 2 cycles)
Concurrent therapy:
Carboplatin AUC  2
Paclitaxel 40 mg/m2 on days 1, 8, 15,
22, 29, and 36
60 22 19.5
Systemic therapy:
Carboplatin AUC  5 on day 1
Paclitaxel 200 mg/m2 on day 1
(every 3 weeks for 2 cycles)
Abbreviations: AUC, area under the curve; CI, confidence interval; MVP, mitomycin, vindesine, cisplatin.
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ter OS result in patients with squamous cancer of the head and
neck [20].
For advanced NSCLC, a phase III trial of cisplatin and vi-
norelbine alone and with cetuximab revealed a statistically sig-
nificant longer OS time with the addition of cetuximab [21].
The Radiation Therapy Oncology Group (RTOG) trial 0324
was a single-arm, phase II trial that investigated weekly cetux-
imab, carboplatin, and paclitaxel concurrent with TRT (63 Gy)
followed by weekly cetuximab, carboplatin, and paclitaxel ev-
ery 21 days for two cycles [22]. The median OS time observed
was 22.7 months (95% CI, 15.3–30.4 months). The Cancer and
Leukemia Group B (CALGB) 30407 trial investigated carbo-
platin and pemetrexed alone and with cetuximab concurrent
with TRT followed by single-agent pemetrexed [13]. Impor-
tantly, this was a nonrandomized phase II trial and was not de-
signed to compare the efficacies of the two treatment arms. The
failure-free survival and OS outcomes observed in the two
arms were similar. Those trials revealed acceptable toxicity
with the addition of cetuximab.
The RTOG 0617 study randomized patients to standard-
dose or high-dose TRT (60 Gy versus 74 Gy) or carboplatin
and paclitaxel alone or with cetuximab concurrent with TRT
for two cycles after completion of TRT (ClinicalTrials.gov
identifier, NCT00533949) [23]. That trial has completed ac-
crual, and the results from the cetuximab comparison are pend-
ing (the results of 60 Gy compared with 74 Gy are discussed
later in the article). The role of cetuximab in the treatment of
stage III NSCLC will be unclear until the results of the RTOG
0617 trial are available.
The EGFR TKIs erlotinib and gefitinib (not commercially
available in the U.S.) are proven agents in the advanced disease
setting in patients who have experienced disease progression
after chemotherapy and in the first-line setting in patients
whose tumors have an activating EGFR mutation [24 –29].













Govindan et al.13 Arm A:
Carboplatin (AUC  5)
Pemetrexed (500 mg/m2) every
21 daysa  4, followed by
pemetrexed (500 mg/m2)  4
48 70 21.2 (17.1-NA)
Arm B:
Carboplatin (AUC  5)
Pemetrexed (500 mg/m2)
Cetuximaba  4 followed by
pemetrexed (500 mg/m2)  4
53 70 25.2 (14.4-NA)
Gadgeel et al.14 Cisplatin (75 mg/m2)
Pemetrexed (500 mg/m2) every
21 days  3 followed by
docetaxel (75 mg/m2) every 21
days  3b
28 66 34
Xu et al.16 Carboplatin (AUC  5)
Pemetrexed (500 mg/m2) every
21 days  5 cycles
21 60–66 NA
Brade et al.15 Cisplatin 20 mg/m2 on days 1–5
Pemetrexed (500 mg/m2) every
21 days  4 cycles
39 61–66 19.7
Choy et al.17 Arm A:
Carboplatin (AUC  5)
Pemetrexed (500 mg/m2) every
21 days  3 followed by




Pemetrexed (500 mg/m2)  3
followed by pemetrexed (500
mg/m2)  3
38c 64–68 NA
aThe first 19 patients received carboplatin (AUC  6).
bThe first 5 patients received cisplatin 60 mg/m2.
cTrial is currently in progress and still enrolling patients.
Abbreviations: AUC, area under the curve; CI, confidence interval; NA, not available.
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Carboplatin (AUC  2), paclitaxel (45
mg/m2) weekly and cetuximab
87 63 22.7 (15.3–30.4)
Consolidation:
Carboplatin (AUC  6), paclitaxel (200
mg/m2) every 3 weeks for 2 cycles,




Carboplatin (AUC  5), pemetrexed
(500 mg/m2) every 3 weeks and
cetuximab weeklya
53 70 25.2 (14.4-NA)
Consolidation:





Cisplatin 50 mg/m2 on days 1,8, 28, 35
Etoposide 50 mg/m2 on days 1–5, 28–33








Poor riskc Poor risk: 21 66 19
Induction:
Carboplatin (AUC  6), paclitaxel (200
mg/m2) every 3 weeks for 2 cycles and
gefitinib 250 mg daily
Concurrent:
Gefitinib 250 mg daily
Consolidation:
Gefitinib 250 mg daily
Good riskc Good risk: 39 13
Induction:
Carboplatin (AUC  6), paclitaxel (200
mg/m2) every 3 weeks for 2 cycles and
gefitinib 250 mg daily
Concurrent:
Carboplatin (AUC  2) and paclitaxel
(50 mg/m2) weekly, gefitinib 250 mg
daily
Consolidation:




Carboplatin (AUC  2), paclitaxel (45
mg/m2) on Monday, erlotinib 150 mg




Carboplatin (AUC  6) and paclitaxel
(200 mg/m2) for 2 cycles
aThis data represents one arm of a randomized phase II trials. The first 19 patients on trial received carboplatin (AUC  6).
bNumbers represent patients randomized to gefitinib or placebo after completion of cisplatin/etoposide and concurrent
thoracic radiation therapy and docetaxel.
cPoor risk was defined as 5% weight loss and/or performance status of 2. Good risk was defined as weight loss 5% and
performance status of 0–1.
Abbreviation: AUC: area under the curve.
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The Southwest Oncology Group trial S0023 investigated
maintenance gefitinib versus placebo after concurrent chemo-
radiotherapy with cisplatin and etoposide and TRT and single-
agent docetaxel [30]. That trial was closed after an unplanned
interim analysis revealed an inferior survival outcome among
patients assigned to the gefitinib arm, compared with the pla-
cebo arm (HR, 0.633; 95% CI, 0.44–0.91; p  .013; median
survival times of 23 months and 35 months, respectively). The
shorter survival time was related to tumor progression, and not
gefitinib toxicity. A phase III trial investigated erlotinib after
concurrent chemoradiotherapy. In the intent-to-treat patient
population, no difference in the primary endpoint of the pro-
gression-free survival interval, was observed [31]. These trials
indicate that EGFR TKI therapy after chemoradiotherapy is
unlikely to be beneficial in an unselected patient population
and may be detrimental.
EGFR TKIs act as a radiation sensitizer when given with
radiation therapy [32, 33]. Several phase I and II trials have
investigated EGFR TKIs in combination with chemotherapy
and concurrent TRT in patients who were not selected by clin-
ical or molecular criteria (Table 3) [34–40]. Those trials have
not revealed excessive overall toxicity and the OS times ob-
served have been variable, probably reflecting differences in
the patients enrolled in the trials. Interstitial pneumonitis is a
rare and potentially fatal adverse event of single-agent EGFR
TKI therapy, and Japanese patients appear to have a higher risk
for this complication [41]. Of note, a higher rate of pulmonary
toxicity has been observed in some trials of concurrent EGFR
TKIs and TRT [42–44].
The predictive value of activating EGFR mutations has
revolutionized the use of these agents in the advanced disease
setting. Data on the predictive value of EGFR mutations in the
stage III setting are limited. Retrospective data on EGFR mu-
tation status are available from the CALGB 30106 trial [39].
The CALGB 30106 study assigned patients to different treat-
ment arms based on performance status and the presence or ab-
sence of weight loss. Patients in both cohorts received gefitinib
as induction, concurrent, and consolidation therapy; patients in
the poor-risk cohort received concurrent TRT and patients in
the good-risk cohort received carboplatin, paclitaxel, and ge-
fitinib concurrent with TRT (66 Gy in both cohorts). In all, 13
of the 45 tumors analyzed had an activating EGFR mutation;
two of these 13 tumors had T790M mutations detected. In an
OS analysis performed on patients with activating EGFR mu-
tations without the T790M mutation (n  11), the median OS
time observed was 8.5 months (95% CI, 5.6–54.4 months); the
median survival time in the poor-risk cohort (n  5) was 28.4
months (95% CI, 5.6–54.4) and the median survival time in the
good-risk cohort (n  6) was 7.2 months (95% CI, 4.7–17.2
months). The poor survival outcome among the small number
of patients in the good-risk cohort with an EGFR mutation is
concerning given the efficacy of EGFR TKI therapy in ad-
vanced-stage disease. There is concern that concurrent chemo-
therapy and EGFR TKI therapy may be antagonistic, which
could be an explanation for the results seen in patients in the
good-risk cohort [45]. However, similar outcomes were ob-
served in the advanced-disease setting with erlotinib alone and
in combination with chemotherapy among patients with EGFR
mutations and those with wild-type EGFR [46].
A phase II trial by Komaki et al. [40] investigated concur-
rent erlotinib, carboplatin, and paclitaxel with TRT, and an
EGFR mutation analysis was performed on 41 tumor samples.
EGFR mutations were detected in five samples. The local con-
trol rate was significantly higher among patients with an EGFR
mutation than among those with wild-type EGFR. Unfortu-
nately, limited data are available on the outcomes of patients
Figure 1. Tracheoesophageal fistula.
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with stage III disease and a known EGFR mutation treated with
chemoradiotherapy or an EGFR TKI concurrent with TRT. In
the advanced disease setting, the presence of a mutation is as-
sociated with a better prognosis, which further complicates the
interpretation of the results.
Bevacizumab
Phase III trials of platinum-based therapy in combination with
bevacizumab compared with platinum-based therapy alone
have shown a higher response rate, longer progression-free
survival interval, and longer OS time in one trial [47–49]. Pre-
clinical and clinical data suggest that antiangiogenesis therapy
and radiation therapy would be additive [50–52]. However,
the development of tracheoesophageal fistulae (Fig. 1) in two
phase II trials led to early closure of the trials, U.S. Food and
Drug Administration warnings, and a change in the bevaci-
zumab package labeling [53]. Of the 25 patients enrolled in the
two trials, suspected or confirmed tracheoesophageal fistulae
were observed in five patients.
A multicenter phase I/II trial investigated bevacizumab as
induction, concurrent, and consolidation therapy (n  45); be-
vacizumab was used with carboplatin and paclitaxel during in-
duction, alone or with erlotinib depending on the patient cohort
during concurrent therapy, and with erlotinib as consolidation
therapy [54]. A high rate of grade 3 esophagitis (29%) was ob-
served, including one tracheoesophageal fistula. The median
OS time observed was 18.7 months (95% CI, 13.4 –33.2
months). The data to date with bevacizumab indicate a high
rate of toxicity, and the limited efficacy data do not suggest a
benefit. It is unlikely that this agent will be developed further in
the stage III setting.
Vaccine Therapy
There has been interest in developing vaccine therapy as a
treatment for a variety of stages of NSCLC. Mucin 1 (MUC1)
is a protein that is overly expressed in NSCLC with abnormal
glycosylation [55]. The BLP25 liposome vaccine (L-BLP25)
induces a cellular immune response that may lead to eradica-
tion of tumor cells that express MUC1 [55]. A phase IIB trial
compared L-BLP25 with best supportive care (BSC) in pa-
tients with locally advanced and advanced NSCLC after first-
line chemotherapy. In the intent-to-treat population, a
statistical difference in the OS time was not observed. How-
ever, in the subset of patients with stage IIIB disease (without
pleural effusion), a trend toward a better OS outcome in the
L-BLP25 arm than in the BSC arm was observed (HR, 0.524;
95% CI, 0.261–1.052; p  .069; the median survival times
were not reached and 13.3 months, respectively). The most
common treatment-related adverse events observed were
grade 1 injection site reactions and flu-like symptoms.
A multinational phase III trial sponsored by Merck KGaA
is currently investigating L-BLP25 compared with BSC in pa-
tients who have completed chemoradiotherapy (ClinicalTri-
als.gov identifier, NCT00409188) [56]. Patients are required
to have radiographic evidence of stable disease or a response
after concurrent or sequential chemotherapy (at least two cy-
cles of platinum-based chemotherapy) and TRT (minimum
dose 50 Gy). Patients are randomized after completion of
chemoradiotherapy, and the planned accrual for this trial is
1,500 patients. The primary endpoint is the OS time, and sec-
ondary endpoints are time to symptoms and tumor progression.
A phase III trial with similar eligibility criteria is being per-
formed in Asia (ClinicalTrials.gov identifier, NCT01015443)
and will enroll 420 patients [56].
Personalized Medicine
For advanced disease, there is great interest in selecting thera-
pies based on biomarkers that are predictive of benefit. The dif-
ference between nonsquamous and squamous histology is a
commonly used criterion for the selection of agents for ad-
vanced disease. It is unclear if the modest improvements in the
OS duration observed among patients with nonsquamous his-
tology with pemetrexed in the advanced disease setting [57]
will result in substantial improvements in long-term survival
outcomes in the stage III setting.
The identification of EGFR mutation for the selection of
EGFR TKIs and anaplastic lymphoma kinase rearrangements
for the development and selection of crizotinib have revolu-
tionized the treatment of advanced-stage disease [58, 59].
These agents have not been evaluated in the stage III setting in
patients selected based on molecular characteristics. The in-
vestigation of crizotinib and EGFR TKI therapy in the stage III
setting will be difficult because only a small percentage of pa-
tients with NSCLC have the associated molecular characteris-
tic, and only a fraction of those patients have stage III disease.
It is also unclear if these agents should be given as induction
therapy prior to TRT to induce response and reduce tumor vol-
ume, alone or with chemotherapy concurrent with TRT, or as
consolidation to prevent disease progression. Patients in the
control arm will undoubtedly receive these agents at the time
of progression, which will confound the OS endpoint. Thus,
the integration of these agents to the stage III setting will be
challenging.
Of the targeted agents investigated in the stage III setting,
cetuximab is furthest in development and the results from the
RTOG 0617 trial may be available in the next year. A retro-
spective analysis of a phase III trial of cisplatin and vinorelbine
alone or with cetuximab for advanced disease revealed that a
composite score of EGFR immunohistochemistry staining in-
tensity and percentage of tumor cells with EGFR expression
was predictive of the benefit of cetuximab; a high score was
observed in 345 patients (31%) and a low score was seen in 776
patients (69%) [60]. Among patients with a high score, the ad-
dition of cetuximab compared with chemotherapy alone re-
sulted in a superior OS outcome (HR, 0.73; 95% CI, 058–0.93;
p  .011; the median OS times were 12.0 months and 9.6
months, respectively). In patients with a low score, no differ-
ence in the OS time was observed with the addition of cetux-
imab compared with chemotherapy alone (HR, 0.99; 95% CI,
0.84–1.16; p  .88; the median OS times were 9.8 months and
10.3 months, respectively). A treatment interaction test be-
tween EGFR score and cetuximab benefit for OS was signifi-
cant (p  .044). The inevitable question is whether or not the
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benefit of cetuximab in the stage III setting is restricted to pa-
tients in the EGFR high-score cohort.
TRT CONSIDERATIONS
Early results from the RTOG 0617 trial, which compared con-
ventionally fractionated standard-dose (60 Gy) or high-dose
(74 Gy) conformal TRT with concurrent carboplatin and pac-
litaxel in stage III NSCLC patients, were recently reported
[61]. Not only was there a lack of a survival benefit for patients
assigned to receive 74 Gy in 2-Gy daily fractions, but there was
a trend toward a lower 1-year survival rate in the high-dose arm
(1-year OS rate, 81% versus 70.4%). The median OS times ob-
served in the low-dose and high-dose arms were 21.7 months
and 20.7 months, respectively (p  .02). The reason for the
poor outcomes in the 74-Gy arm has not been clearly eluci-
dated, although greater toxicity was not observed with higher
radiation doses. Mature follow-up and assessment of failure
patterns are necessary to fully understand the nature of these
results, but the strategy of conventional dose escalation via a
longer duration of TRT must be called into question.
Although several prospective phase I/II cooperative group
studies suggested encouraging OS results with 74-Gy TRT,
outcomes may have been biased by the selection of a relatively
favorable group of patients, given that these studies were
among the first trials to routinely include FDG-PET imaging
for staging evaluation [62–64]. In addition, some trials had
quite restrictive dose constraints, particularly regarding the al-
lowed exposure of the uninvolved lung volume of 20 Gy (e.g.,
V20), which could have led to enrolling patients with relatively
limited tumor burdens. It is perhaps sobering to note that the
3-year OS rate in the standard arm of the recent phase III Hoo-
sier Oncology Group trial was among the best reported, al-
though a lower TRT dose (59.4 Gy) than in contemporaneous
studies was given [65].
Despite the lack of benefit noted with high-dose TRT in the
RTOG 0617 trial, the relative impact of better local tumor con-
trol in a disease ruled by systemic relapse was highlighted in
the recent meta-analysis of sequential versus concurrent che-
moradiotherapy in stage III NSCLC patients (described ear-
lier) [4]. Both seminal trials that established concurrent
therapy as the standard of care also suggested that the superior
OS outcome was, in large part, a result of enhanced locore-
gional control. In the RTOG 94–10 trial, the 2-year infield re-
lapse rate was lower, 30% versus 39%, whereas the long-term
intrathoracic tumor control rate was higher, 50% versus 35%,
in the West Japan Lung Cancer Group Trial [5, 6]. Therefore, it
seems that strategies focused on further enhancing local tumor
control may translate to meaningful improvements in OS out-
comes. However, whether or not modulating the TRT regimen
can result in better outcomes as part of combined modality
therapy remains to be determined.
Although disappointing, the results of the RTOG 0617 trial
add to the body of clinical and preclinical evidence suggesting
that extending the duration of conventional radiotherapy may
result in diminished efficacy [66]. This was suggested in ret-
rospective analyses of RTOG NSCLC trials [67], and a strik-
ingly similar outcome to that of the RTOG 0617 trial was
observed in an intergroup study comparing high-dose and stan-
dard-dose radiotherapy concurrent with chemotherapy for lo-
cally advanced esophageal cancer [68].
On the other hand, increasing the TRT dose intensity by
accelerating the time to complete therapy may be a more at-
tractive strategy. The U.K. trial of continuous hyperfraction-
ated accelerated radiotherapy (CHART), which used 54 Gy in
36 fractions of 1.5 Gy over 12 consecutive days, is one of the
few phase III trials to demonstrate that changing the way TRT
is administered can result in a better OS outcome [69]. An ab-
solute 9% greater 2-year OS rate was demonstrated with
CHART compared with conventional TRT (60 Gy).
The Eastern Cooperative Oncology Group studied a varia-
tion of CHART, which employed thrice-daily TRT but elimi-
nated therapy during weekends [70, 71]. In a phase III trial,
after two cycles of induction carboplatin and paclitaxel che-
motherapy, patients were randomized to standard TRT or
HART [71]. Although the trial closed prematurely, the median
survival time was 20.3 months for HART, compared with 14.9
months with standard TRT. The difference did not reach sta-
tistical significance, but the results with HART compare favor-
ably with those from trials of simultaneous chemoradiotherapy
and suggest a potential impact of TRT dose intensity.
The application of HART is limited by the logistic consid-
erations of treating patients multiple times in a day. Moreover,
combining CHART with concurrent chemoradiotherapy is
challenging in light of the greater acute (esophageal) toxicity
observed with hyperfractionated therapy. An alternative ap-
proach that has been gaining traction, in large part because of
recent advances in technology, is the administration of higher
daily doses of radiotherapy, which allows treatment to be com-
pleted in fewer fractions (e.g., hypofractionation) than with
conventional TRT.
The potential of hypofractionation for locally advanced
NSCLC was recognized as early as the 1980s. The RTOG
83–12 trial employed a dose schema of 75 Gy in 2.68-Gy frac-
tions for unresectable (T3/T4) NSCLC [72]. Although rudi-
mentary treatment planning was used, treatment was well
tolerated, with outcomes in line with those of contemporane-
ous studies of primary TRT. Whether or not accelerated hypo-
fractionated TRT and accelerated hyperfractionated TRT have
similar efficacies is unclear, although a hypofractionated reg-
imen (55 Gy in 2.75-Gy fractions) appeared equivalent to
CHART in a retrospective analysis of patients with unresect-
able NSCLC in the U.K. [73].
More recent trials have assessed hypofractionated TRT
regimens in the context of combined modality therapy. The
practical attraction of completing therapy in fewer overall
treatments is clear in a system for which machine accessibility
and costs are constrained. The European Organization for Re-
search and Treatment of Cancer (EORTC) 08912 trial was a
phase I/II study of hypofractionated TRT with concurrent che-
motherapy for inoperable patients [74]. Daily cisplatin chemo-
therapy (6 mg/m2) was administered with 2.75-Gy fractions,
and the TRT dose was escalated from 60.5 Gy to 66 Gy without
unexpected acute adverse events. Late esophageal toxicity cor-
related with high-dose (e.g., 55 Gy) exposure to the esophagus.
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A subsequent phase III trial (EORTC 08972) randomized
158 patients to receive concurrent daily cisplatin with TRT
or two cycles of induction gemcitabine and cisplatin followed
by TRT [75]. Radiotherapy consisted of 66 Gy in 2.75-Gy frac-
tions, with elective nodal irradiation to 40 Gy in 2-Gy frac-
tions. The trial was closed early because of slow accrual, and
therefore it was underpowered to detect significant differences
in OS outcomes. Nevertheless, the 3-year OS rate was 34% in
patients receiving concurrent treatment, compared with 22%
for patients receiving sequential treatment, thus suggesting a
possible long-term benefit. Treatment-related adverse effects
in the concurrent arm appeared similar to those in other series
of concurrent therapy, although acute toxicity was less in the
sequential arm.
A major concern with hypofractionated therapy is the po-
tential higher rate of late effects when large fractions are given
to critical normal structures. To address this concern, recent
trials of concurrent chemotherapy and hypofractionated TRT
have eliminated elective nodal irradiation and instead have fo-
cused on intensifying TRT to areas of known tumor. A ran-
domized phase II trial from the U.K. assessed hypofractionated
TRT (55 Gy in 2.75-Gy fractions) with concurrent or sequen-
tial cisplatin and vinorelbine chemotherapy. Overall, 130 pa-
tients with inoperable stage III NSCLC were included in the
study [76]. Modern radiotherapy techniques, including four-
dimensional treatment planning to assess tumor motion during
respiration, were employed. The planning target volume
(PTV) was limited to the gross target volume (GTV) plus a
margin of 1 cm. With a median follow-up of 25 months, the
median survival time for patients receiving concurrent chemo-
therapy with hypofractionated radiotherapy was 27.4 months,
compared with 18.6 months for those receiving sequential treat-
ment. Overall, the toxicity profile of concurrent chemotherapy
with hypofractionated chemotherapy was similar to that seen in
the sequential arm. However, it is important to note that, in an ear-
lier hypofractionated TRT retrospective series reported by this
group, eight of 104 patients required dilatation for esophageal
strictures [77].
A single-arm, prospective, phase II study by the Korean
Radiation Oncology Group likewise reported encouraging out-
comes for hypofractionated TRT and concurrent chemoradio-
therapy for patients with unresectable stage III NSCLC [78].
Conformal TRT was given in daily 2.4-Gy fractions with
weekly paclitaxel (50 mg/m2) and carboplatin (area under the
concentration–time curve of 2) chemotherapy. In that study,
PTV expansions from the GTV of 1.5–2.5 cm were allowed
because four-dimensional planning was not routinely used. Af-
ter a median follow-up of 36.8 months for surviving patients,
the median OS time for all 49 study patients was 28.1 months.
Severe toxicity appeared limited, although two patients with
T4 lesions experienced grade 5 hemoptysis and three patients
developed late esophageal strictures.
The previously described trials suggest a greater therapeu-
tic ratio with hypofractionated TRT, but more robust clinical
evidence is necessary—particularly given concerns about late
associated toxicities. The Alliance for Clinical Trials in Oncol-
ogy Network cooperative group is scheduled to open a phase I
trial assessing hypofractionated RT and weekly carboplatin
plus paclitaxel chemotherapy (ClinicalTrials.gov identifier,
NCT01486602). That study will use a schema of increasing the
dose per fraction while maintaining a constant nominal total
dose of 6000 cGy, resulting in administration of fewer frac-
tions in each successive patient cohort (Table 4). Excellent lo-
cal tumor control, with a low rate of severe toxicity, was
observed in a prior CALGB trial that employed a similar radi-
ation dose per fraction escalation schema in high-risk early-
stage NSCLC patients [79]. Once a maximally tolerated
fraction size has been determined, a phase III comparison with
conventional TRT will be considered. The integration of ad-
vanced technology will be used to minimize expansions of tar-
get volumes and help ensure accuracy of treatment in an effort
to limit doses to critical normal structures. For example, func-
tional imaging with FDG-PET will be employed for target de-
lineation [80], four-dimensional planning and measures to
account for tumor motion will be incorporated, and image-
guided radiotherapy will be performed directly prior to each
fraction to limit target volume expansion [81]. Intensity-mod-
ulated TRT will also be favored to further avoid exposing crit-
ical structures to high-dose TRT. Thus, the trial will serve to
assess hypofractionated TRT for locally advanced NSCLC in
the context of the currently available state-of-the-art advanced
technology, with the hope that these results will translate to the
general stage III population.
Adaptive radiotherapy (AR) uses changes in tumor volume
to adjust the TRT treatment plan during therapy and has been
facilitated by the adoption of daily image guidance in many
practices. AR should result in better protection of normal struc-
tures while ensuring the tumor is adequately dosed. A novel
approach to AR—using changes in FDG-PET imaging during
concurrent therapy to determine both treatment volume and
dose per fraction—will be studied in the RTOG 1106/Ameri-
can College of Radiology Imaging Network 6697 trial [82].
The phase II randomized design will assign patients to receive
either standard TRT or AR with the objective of exploring out-
comes and toxicity of individualized dose escalation. Treat-
ment in the experimental arm is individualized based on
changes in functional imaging obtained midway through treat-
ment, and daily fractions as high as 4.25 Gy will be permitted
for residual PET-avid disease, depending on the predicted tox-
icity of treatment. Both this trial and the Alliance study will
include strict normal tissue constraints, yet at the same time
Table 4. Thoracic radiation therapy (TRT) schema for












1 60.0 2.22 27 5.5
2 60.0 2.50 24 5
3 60.0 2.73 22 4.5
4 60.0 3.00 20 4
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they will allow for greater dose inhomogeneity than in prior
trials to better spare organs at risk. The relationship between
functional imaging characteristics, both at baseline and during
therapy, and outcomes will also be assessed. A separate ran-
domized phase II study ongoing in The Netherlands assigns the
boost TRT volume based on the region of high FDG-PET avid-
ity seen on pretreatment PET imaging in the experimental arm
(ClinicalTrials.gov identifier, NCT01024829) [56]. Hypofrac-
tionated TRT of 66 Gy in 2.75-Gy fractions is administered in
all patients.
More extreme hypofractionation in the form of stereotactic
body radiotherapy (SBRT) has rapidly been adopted into rou-
tine clinical practice for high-risk patients with early-stage
NSCLC based on excellent outcomes in prospective studies
[83]. Although severe toxicity was encountered in early studies
after using SBRT for centrally located lesions (e.g., close to
major airways and critical mediastinal structures), an ongoing
RTOG trial designed specifically for central lesions suggests
that a more protracted five-fraction SBRT regimen may be
well tolerated (ClinicalTrials.gov identifier, NCT00750269)
[84]. Clinical experience using SBRT for locally advanced
NSCLC is limited, but preliminary data suggest that adding an
SBRT boost for residual disease in patients with stage III
NSCLC may be feasible [85]. Additional trials are now assess-
ing the safety and efficacy of SBRT as a boost for residual tu-
mor (based on either anatomic or functional imaging)
following induction chemoradiotherapy (ClinicalTrials.gov
identifier, NCT00945451 and NCT01222572) [56]. These
studies should help determine whether or not SBRT may have
a role in the treatment of select patients with stage III NSCLC.
As the development of proton therapy centers has prolifer-
ated, experience using proton therapy with concurrent chemo-
therapy for locally advanced NSCLC is starting to accumulate
[86, 87]. Protons have distinct physical advantages over con-
ventional photon therapy (e.g., Bragg peak), which should al-
low for better sparing of normal tissues with the potential to
reduce toxicity and facilitate hypofractionated therapy. How-
ever, the heterogeneity of tissues in the chest, including the in-
terface between air in the lung and both tumor and normal
structures, can increase the complexity and uncertainty of pro-
ton TRT planning. Retrospective studies published to date
should be evaluated with caution given the potential for patient
selection, but ongoing prospective trials should provide further
data regarding the safety and initial efficacy of proton therapy
in locally advanced NSCLC (ClinicalTrials.gov identifier,
NCT01076231) [56].
SUMMARY
Stage III NSCLC continues to be a significant clinical chal-
lenge. More recently developed chemotherapy agents appear
to have similar efficacies with lower rates of some toxicities. A
phase III trial of cisplatin plus pemetrexed with concurrent
TRT in patients with nonsquamous histology is ongoing. The
RTOG 0617 trial has completed enrollment and results of the
comparison for carboplatin and paclitaxel alone and for cetux-
imab will determine the role of cetuximab in stage III disease.
The results of these phase III trials will determine the roles of
these agents. Bevacizumab will not have a role in stage III dis-
ease based on the observed toxicity, and the targeted agents er-
lotinib, gefitinib, and crizotinib have yet to be investigated in
patients selected based on molecular characteristics. Prelimi-
nary results of the comparison of 60 Gy versus 74 Gy as part of
the RTOG 0617 trial revealed an inferior OS outcome with the
high-dose treatment arm. Hypofractionation, SBRT, AR, and
proton therapy are currently being investigated for stage III
NSCLC.
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